Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

NCT03520998 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT03520998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2018
Completion date
May 24, 2019
Enrollment
47 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild to moderate alzheimer disease